These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 33514385)

  • 21. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
    Mast FD; Fridy PC; Ketaren NE; Wang J; Jacobs EY; Olivier JP; Sanyal T; Molloy KR; Schmidt F; Rutkowska M; Weisblum Y; Rich LM; Vanderwall ER; Dambrauskas N; Vigdorovich V; Keegan S; Jiler JB; Stein ME; Olinares PDB; Herlands L; Hatziioannou T; Sather DN; Debley JS; Fenyö D; Sali A; Bieniasz PD; Aitchison JD; Chait BT; Rout MP
    Elife; 2021 Dec; 10():. PubMed ID: 34874007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
    Yang Y; Li F; Du L
    J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
    Yao H; Cai H; Li T; Zhou B; Qin W; Lavillette D; Li D
    PLoS Pathog; 2021 Mar; 17(3):e1009328. PubMed ID: 33657135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
    Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
    Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of a Series of Neutralizing Nanobodies against SARS-CoV-2 Spike Protein].
    Zhuchkov VA; Ivanov SV; Kravchenko JE; Chumakov SP
    Mol Biol (Mosk); 2023; 57(3):505-516. PubMed ID: 37326055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
    Dong J; Huang B; Wang B; Titong A; Gallolu Kankanamalage S; Jia Z; Wright M; Parthasarathy P; Liu Y
    Sci Rep; 2020 Oct; 10(1):17806. PubMed ID: 33082473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
    Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
    Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
    MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
    Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
    Viruses; 2023 May; 15(6):. PubMed ID: 37376552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody.
    Singh V; Bhutkar M; Choudhary S; Nehul S; Kumar R; Singla J; Kumar P; Tomar S
    Biochem Biophys Res Commun; 2024 Nov; 734():150746. PubMed ID: 39366179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
    Jiang X; Qin Q; Zhu H; Qian J; Huang Q
    Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation and Characterization of a Nanobody Against SARS-CoV.
    Li JF; He L; Deng YQ; Qi SH; Chen YH; Zhang XL; Hu SX; Fan RW; Zhao GY; Qin CF
    Virol Sin; 2021 Dec; 36(6):1484-1491. PubMed ID: 34403037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals.
    Wu P; Yang Q; Zhao X; Liu Q; Xi J; Zhang F; He J; Yang H; Zhang C; Ma Z; Deng X; Wang Y; Chen C
    Res Vet Sci; 2022 Jul; 145():46-49. PubMed ID: 35152188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.